Milestone Pharmaceuticals (MIST) News Today

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) stock is under pressure after the company’s first-quarter 2026 results showed a much wider-than-expected loss and revenue that fell far short of forecasts, even as management highlighted early progress for its newly launched CARDAMYST treatment.

• Positive Sentiment: Wells Fargo cut its price target to $7 from $8 but kept an Overweight rating, signaling it still sees substantial upside from current levels. Article Title
• Positive Sentiment: Milestone said CARDAMYST launch momentum is building, with about 600 prescriptions filled, roughly 400 unique prescribers, and Express Scripts national formulary coverage now in place, which should improve access and adoption. Article Title
• Positive Sentiment: The company also began a Phase 3 trial in AFib-RVR, giving investors another potential growth driver beyond PSVT. Article Title
• Neutral Sentiment: Milestone will present at the H.C. Wainwright BioConnect Investor Conference on May 19, which could keep attention on the stock but is not a major fundamental catalyst by itself. Article Title
• Negative Sentiment: Q1 EPS came in at -$0.20 versus expectations of -$0.03, and revenue was only $0.24 million versus roughly $30 million expected, underscoring a major miss. Article Title
• Negative Sentiment: The company’s net loss widened to $26.1 million, and commercial spending rose sharply as Milestone ramped the CARDAMYST launch, raising questions about how quickly sales can catch up to expenses. Article Title

Overall, MIST is being weighed down today by the weak quarterly earnings report, while investor optimism is being supported by early CARDAMYST launch traction, payer coverage gains, and a new late-stage development program.